⌕
Surgery Partners · SGRY · Nasdaq
Tenet 49 · Mixed
Compare
$26.69−1.00%At closeTenet 49 · Mixed
$26.69−0.27 (−1.00%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Surgery Partners (SGRY) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~10.4%/yr (FY21→FY25), net margin −2.4%, and free cash flow (~$195.6M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+75.6%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲6.2%
3,308.7
FY21→FY25CAGR +10.4%/yr
Net income ($M)▲53.7%
−77.9
one-off year: see footnoteCAGR —
Free cash flow ($M)▼6.7%
195.6
FY21→FY25CAGR +60.5%/yr
Diluted EPS▲54.1%
−0.61
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+75.6%

72.4mn → 127.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$78.7M

steady at 2.4% of revenue (−12.9% YoY).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)3308.7Revenue−971.0COGS2337.7Gross profit−1603.0SG&A389.5Op income−467.4Tax & other−77.9Net income

-2¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 42.4% → 70.7%. Net margin -2.4% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
3,360,100.03,308,700.03,114,300.02,743,300.02,539,300.02,225,100.0▲6.2%+10.4%
Cost of revenue
578,900.0971,000.01,922,100.01,714,100.01,456,100.01,280,700.0▼49.5%−6.7%
Gross profit
2,781,200.02,337,700.01,192,200.01,029,200.01,083,200.0944,400.0▲96.1%+25.4%
Selling, general & admin
2,079,800.01,603,000.0495,800.0417,700.0528,100.0466,400.0▲223.3%+36.2%
Total operating expenses
2,417,500.01,948,200.0843,400.0701,200.0738,000.0642,200.0▲131.0%+32.0%
Operating incomefeeds ROC rank
363,700.0389,500.0348,800.0328,000.0345,200.0302,200.0▲11.7%+6.5%
Other income, net
−274,400.0−272,600.0−201,700.0−193,000.0−234,900.0−221,000.0——
Pretax income
89,300.0116,900.0147,100.0135,000.0110,300.081,200.0▼20.5%+9.5%
Income tax
18,600.018,000.0134,600.0−300.023,300.010,500.0▼86.6%+14.4%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−87,000.0−77,900.0−168,100.0−11,900.0−54,600.0−70,900.0▲53.7%—
Per share
Diluted EPSbuyback-sensitive
−0.67−0.61−1.33−0.09−0.59−1.12▲54.1%—
Diluted shares (mn)
128.87127.21126.12125.6191.9572.43▲0.9%+15.1%
Margins
Gross margin77th pct in Healthcare
82.8%70.7%38.3%37.5%42.7%42.4%▲32.4pp+28.2pp
Operating margin
10.8%11.8%11.2%12.0%13.6%13.6%▲0.6pp−1.8pp
Net margin35th pct in Healthcare
−2.6%−2.4%−5.4%−0.4%−2.2%−3.2%▲3.0pp+0.8pp
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was −0% vs a 15% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was 92% vs a 15% norm for this window, likely a one-time item; see the filing.
FY13 – FY20 · 7 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Surgery Partners' revenue last fiscal year?

Surgery Partners reported revenue of $3,308.7M in fiscal 2025, up 6.2% from fiscal 2024.

What was Surgery Partners' net income?

Surgery Partners reported net income of −$77.9M in fiscal 2025, a net margin of −2.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.